---
title: "Aqneursa (levacetylleucine) in Ataxia-telangiectasia: References"
description: "Reference list for the formulary evidence report on Aqneursa (levacetylleucine, IB1001) in Ataxia-telangiectasia. 209 cited documents."
canonical: "https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/references"
published: "2026-10-02T18:22:10-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Aqneursa (levacetylleucine) in Ataxia-telangiectasia: References

<a id="references"></a>

## 5 References

1. [Abid et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13649919/)
2. [Akturk et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28120234/)
3. [Amirifar et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30685876/)
4. [Amirifar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32791865/)
5. [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)
6. [ASHP AHFS DI Essentials (2025)](https://www.drugs.com/monograph/levacetylleucine.html)
7. [Ataxia-Telangiectasia Society (2014)](https://atsociety.org.uk/wp-content/uploads/2017/10/A-T_Clinical_Guidance_Document_Final.pdf)
8. [Ataxia-Telangiectasia Society (2026)](https://atsociety.org.uk/wp-content/uploads/2026/03/Clinical-Guidance-13.pdf)
9. [Austin American-Statesman (2024)](https://www.statesman.com/story/news/healthcare/2024/10/01/intrabio-austin-texas-aqneursa-treatment-niemann-pick-disease-help-firefly-fund-sisters/75453460007/)
10. [Bakhtiar et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34337741/)
11. [Becker-Bense et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9813104/)
12. [Benard et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11554437/)
13. [Beresford et al. (2013)](https://eprints.whiterose.ac.uk/id/eprint/77083/1/ATMyLife.pdf)
14. [Beyraghi-Tousi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38669738/)
15. [Bhatt et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9487625/)
16. [Blom et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6851017/)
17. [Brandsma et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24392880/)
18. [Bremova-Ertl et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38294974/)
19. [Brown and Barañano (2026)](https://pubmed.ncbi.nlm.nih.gov/42561491/)
20. [Brueggemann et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34620022/)
21. [Cabana et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9651420/)
22. [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%2C%22Breakthrough%20Therapy%20Indicator%22%2C%22Priority%20Review%20Indicator%22%2C%22General%20Comments%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22NDC%20Number%22%20%3D%20%2783853010101%27)
23. [CarelonRx DrugInsights (2024)](https://carelonrx.com/content/dam/digital/carelon/pdf/DrugInsights-Q424.pdf)
24. [Chessa et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3904207/)
25. [Chopra et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3992040/)
26. [Churchill et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7046201/)
27. [Churchill et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8338929/)
28. [Cigna Healthcare (2025)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0715_coveragepositioncriteria_aqneursa.pdf)
29. [Cirillo et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29489040/)
30. [Cirillo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166859/)
31. [ClinicalTrials.gov NCT03759678](https://clinicaltrials.gov/study/NCT03759678)
32. [ClinicalTrials.gov NCT03759678 API record](https://clinicaltrials.gov/api/v2/studies/NCT03759678)
33. [ClinicalTrials.gov NCT03759678 results](https://clinicaltrials.gov/study/NCT03759678?tab=results)
34. [ClinicalTrials.gov NCT06193200](https://clinicaltrials.gov/study/NCT06193200)
35. [ClinicalTrials.gov NCT06673056](https://clinicaltrials.gov/study/NCT06673056)
36. [ClinicalTrials.gov NCT07221292](https://clinicaltrials.gov/study/NCT07221292)
37. [ClinicalTrials.gov NCT07380165](https://clinicaltrials.gov/study/NCT07380165)
38. [Collyer and Rajan (2024)](https://pubmed.ncbi.nlm.nih.gov/39622612/)
39. [Coman et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41151249/)
40. [Crawford et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10751267/)
41. [Crawford et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2082822/)
42. [CTIS 2024-517706-29](https://euclinicaltrials.eu/ctis-public/view/2024-517706-29-00)
43. [Curant Health (2024)](https://curanthealth.com/curant-health-selected-by-intrabio-as-the-exclusive-specialty-pharmacy-for-aqneursa-levacetylleucine-the-first-stand-alone-therapy-for-niemann-pick-disease-type-c/)
44. [Curant Health (2026)](https://curanthealth.com/curant-rare-and-intrabio-bring-real-world-evidence-to-niemann-pick-disease-type-c-care/)
45. [Davis et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13378962/)
46. [de Leon et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12220173/)
47. [DelveInsight (2026)](https://www.delveinsight.com/report-store/levacetylleucine%20-sales-forecast-and-market-size-analysis)
48. [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx)
49. [Devaney et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27799156/)
50. [Donath et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6856634/)
51. [Donath et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7363802/)
52. [Donath et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8885493/)
53. [Drugs.com Aqneursa price guide](https://www.drugs.com/price-guide/aqneursa)
54. [Drugs@FDA NDA 219132](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219132)
55. [Dutzmann et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8683217/)
56. [Elitzur et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13122324/)
57. [European Medicines Agency Aqneursa assessment report (2025)](https://www.ema.europa.eu/en/documents/assessment-report/aqneursa-epar-public-assessment-report_en.pdf)
58. [European Medicines Agency Aqneursa EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/aqneursa)
59. [European Medicines Agency Aqneursa product information (2026)](https://www.ema.europa.eu/en/documents/product-information/aqneursa-epar-product-information_en.pdf)
60. [European Medicines Agency CHMP agenda (2026)](https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-14-17-september-2026_en.pdf)
61. [European Medicines Agency CHMP meeting highlights (2026)](https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2026)
62. [European Medicines Agency orphan designation EU/3/18/2124 (2019)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2124)
63. [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-niemann-pick-disease-type-c)
64. [FDA (2026)](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-therapy-treat-ataxia-patients-ataxia-telangiectasia-rare-genetic-disorder)
65. [FDA Federal Register notice (2024)](https://www.govinfo.gov/content/pkg/FR-2024-10-15/html/2024-23712.htm)
66. [FDA integrated review (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/219132Orig1s000IntegratedR.pdf)
67. [FDA NDA approval letter (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/219132Orig1s000ltr.pdf)
68. [FDA Orange Book (2026)](https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=219132&Appl_type=N)
69. [FDA Orphan Drug Designations and Approvals (2018)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=653218)
70. [FDA supplement approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219132Orig1s002ltr.pdf)
71. [Feil et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8672236/)
72. [Félix et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/23956159/)
73. [Fields et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7821839/)
74. [Fields et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226221/)
75. [Fierce Pharma FDA approval report (2026)](https://www.fiercepharma.com/pharma/intrabio-scores-aqneursa-expansion-now-first-treatment-globally-rare-ataxia)
76. [Fierce Pharma phase 3 results report (2026)](https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win)
77. [Günther et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4372420/)
78. [Hasegawa et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31272782/)
79. [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ib1001-203/)
80. [Hegdekar et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8084982/)
81. [Hensiek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42634970/)
82. [Hoche et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30338439/)
83. [Horn et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13359211/)
84. [IntraBio AQNEURSA ataxia-telangiectasia website (2026)](https://www.aqneursa.com/at/)
85. [IntraBio AQNEURSA Cares healthcare professional brochure (2024)](https://www.aqneursa.com/wp-content/aqneursa-cares-hcp-brochure.pdf)
86. [IntraBio AQNEURSA Cares patient brochure (2024)](https://www.aqneursa.com/wp-content/aqneursa-cares-patient-brochure.pdf)
87. [IntraBio AQNEURSA healthcare professional website (2026)](https://www.aqneursahcp.com/access-and-resources/)
88. [IntraBio AQNEURSA patient enrollment form (2026)](https://www.aqneursa.com/wp-content/enrollment-form.pdf)
89. [IntraBio AQNEURSA prior authorization checklist (2026)](https://www.aqneursahcp.com/wp-content/prior-authorization-checklist.pdf)
90. [IntraBio CACNA1A trial authorization release (2026)](https://www.biospace.com/press-releases/intrabio-receives-regulatory-authorization-to-begin-pivotal-phase-iii-trial-of-levacetylleucine-in-cacna1a-related-disorders-across-participating-regions)
91. [IntraBio CHMP positive opinion release (2025)](https://www.biospace.com/press-releases/aqneursa-levacetylleucine-recommended-for-eu-approval-by-the-chmp-to-treat-niemann-pick-disease-type-c)
92. [IntraBio EMA variation release (2026)](https://www.biospace.com/press-releases/intrabio-announces-submission-of-variation-application-to-the-european-medicines-agency-for-aqneursa-for-ataxia-telangiectasia)
93. [IntraBio Expanded Access Policy (2026)](https://intrabio.com/expanded-access-policy/)
94. [IntraBio FDA approval release (2026)](https://www.biospace.com/press-releases/intrabio-announces-u-s-fda-approval-of-aqneursa-levacetylleucine-for-ataxia-telangiectasia)
95. [IntraBio further detail release (2026)](https://www.biospace.com/press-releases/intrabio-reports-further-detail-on-positive-data-from-levacetylleucine-pivotal-trial-for-the-treatment-of-ataxia-telangiectasia)
96. [IntraBio IB1001-203 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/78/NCT03759678/Prot_000.pdf)
97. [IntraBio IB1001-203 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/78/NCT03759678/SAP_001.pdf)
98. [IntraBio patient community letter (2024)](https://nnpdf.org/wp-content/uploads/2024/09/IntraBio-NPC-Patient-Community-Letter-09.25.2024.pdf)
99. [IntraBio priority review release (2026)](https://www.biospace.com/press-releases/fda-accepts-snda-and-grants-priority-review-to-aqneursa-for-ataxia-telangiectasia)
100. [IntraBio sNDA submission release (2026)](https://www.biospace.com/press-releases/intrabio-announces-submission-of-supplemental-new-drug-application-for-levacetylleucine-for-ataxia-telangiectasia)
101. [IntraBio topline results release (2026)](https://www.biospace.com/press-releases/intrabio-announces-positive-pivotal-trial-results-of-levacetylleucine-for-the-treatment-of-ataxia-telangiectasia)
102. [IntraBio Virtual Patent Marking (2026)](https://intrabio.com/patents/)
103. [IRCT IRCT20210413050958N1](https://en.irct.ir/trial/56693)
104. [Jackson et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26896183/)
105. [Kaya et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7230825/)
106. [Kaya et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7954382/)
107. [Kelly et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8993771/)
108. [Khan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10148630/)
109. [Koenig et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11800360/)
110. [Krauthammer et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29290356/)
111. [Kridli et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38231422/)
112. [Lawerman et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28815574/)
113. [Lefton-Greif et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10657830/)
114. [Lefton-Greif et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3116459/)
115. [Leuzzi et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4396528/)
116. [Levy and Lang (2018)](https://pubmed.ncbi.nlm.nih.gov/29436738/)
117. [Lindahl et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10884802/)
118. [Lockman et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/21478798/)
119. [Lynch et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12271818/)
120. [Magnarelli et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11915532/)
121. [Major et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10951025/)
122. [Mallott et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3591536/)
123. [Mandola et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6932992/)
124. [Martakis et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42309084/)
125. [Martakis et al. supplementary appendix (2026)](https://ars.els-cdn.com/content/image/1-s2.0-S1474442226001584-mmc1.pdf)
126. [McGlashan et al. (2022)](https://www.ejpn-journal.com/article/S1090-3798(22)00115-5/fulltext)
127. [McGrath-Morrow et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4151879/)
128. [McGrath-Morrow et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4423797/)
129. [McGrath-Morrow et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8253936/)
130. [Medicaid.gov State Drug Utilization Data 2025 (2026)](https://data.medicaid.gov/api/1/datastore/query/158a1baa-5506-400a-8ec3-97756f0b0536/0?conditions%5B0%5D%5Bproperty%5D=ndc&conditions%5B0%5D%5Bvalue%5D=83853010101&conditions%5B0%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=20&properties%5B%5D=utilization_type&properties%5B%5D=state&properties%5B%5D=ndc&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=product_name&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&properties%5B%5D=medicaid_amount_reimbursed&properties%5B%5D=non_medicaid_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=quarter&sorts%5B0%5D%5Border%5D=asc&schema=false&keys=true&count=false)
131. [Medicaid.gov State Drug Utilization Data 2026 (2026)](https://data.medicaid.gov/api/1/datastore/query/2957a7f9-9a15-453e-9afd-3bbdcbac8fd3/0?conditions%5B0%5D%5Bproperty%5D=ndc&conditions%5B0%5D%5Bvalue%5D=83853010101&conditions%5B0%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bproperty%5D=state&conditions%5B1%5D%5Bvalue%5D=XX&conditions%5B1%5D%5Boperator%5D=%3D&limit=20&properties%5B%5D=utilization_type&properties%5B%5D=state&properties%5B%5D=ndc&properties%5B%5D=year&properties%5B%5D=quarter&properties%5B%5D=suppression_used&properties%5B%5D=product_name&properties%5B%5D=units_reimbursed&properties%5B%5D=number_of_prescriptions&properties%5B%5D=total_amount_reimbursed&properties%5B%5D=medicaid_amount_reimbursed&properties%5B%5D=non_medicaid_amount_reimbursed&sorts%5B0%5D%5Bproperty%5D=quarter&sorts%5B0%5D%5Border%5D=asc&schema=false&keys=true&count=false)
132. [Medical Mutual (2025)](https://www.medmutual.com/-/media/MedMutual/Files/Providers/Prior-Auth-Rx/Aqneursa.pdf)
133. [MedlinePlus Genetics (2022)](https://medlineplus.gov/genetics/condition/ataxia-telangiectasia/)
134. [Mehri et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39327359/)
135. [Micol et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21665257/)
136. [Morrell et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3459930/)
137. [Natale et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7945359/)
138. [National Organization for Rare Disorders (2022)](https://rarediseases.org/rare-diseases/ataxia-telangiectasia/)
139. [New York State Medicaid eMedNY](https://www.emedny.org/info/formfile.aspx)
140. [New York State Medicaid list of reimbursable drugs (2026)](https://docs.emedny.org/ReimbursableDrugs/MedReimbDrugsFormulary.csv)
141. [NHS England (2013)](https://www.england.nhs.uk/wp-content/uploads/2018/08/Ataxia-telangiectasia-service-adult.pdf)
142. [Nissenkorn et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22550086/)
143. [Nissenkorn et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26493850/)
144. [Nowak-Wegrzyn et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15069401/)
145. [Oklahoma Health Care Authority Drug Utilization Review Board packet (2025)](https://oklahoma.gov/content/dam/ok/en/okhca/docs/about/boards-and-committees/dur/2025/march/03122025%20DUR%20Packet.pdf)
146. [openFDA NDC Directory (2026)](https://api.fda.gov/drug/ndc.json?search=brand_name:aqneursa)
147. [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)
148. [Padilla et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12487891/)
149. [Panvino et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13323561/)
150. [Park et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11447074/)
151. [Patterson et al. (2025)](https://www.mdscongress.org/IC25_LBAs.pdf)
152. [Patterson et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-006221.html)
153. [Patterson et al. (2026b)](https://www.aan.com/msa/public/events/abstractdetails/62691)
154. [Pereira et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38834764/)
155. [Perez-Lloret et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33022077/)
156. [Petley et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9049793/)
157. [Potashman et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489265/)
158. [Potashman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489232/)
159. [Presterud et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37899683/)
160. [Quince Therapeutics topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1662774/000119312526029524/d61547dex991.htm)
161. [Rehm et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13485601/)
162. [Reiman et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3170966/)
163. [Rothblum-Oviatt et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5123280/)
164. [Ruano et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24603320/)
165. [Russo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42600624/)
166. [Saberi-Karimian et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35128617/)
167. [Schmitz-Hübsch et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16769946/)
168. [Schmitz-Hübsch et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18695159/)
169. [Schmitz-Hübsch et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20177122/)
170. [Schoenaker et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6970962/)
171. [Schon et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6590299/)
172. [Schroeder et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15789441/)
173. [Shaikh et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23884713/)
174. [Shiloh (2020)](https://pubmed.ncbi.nlm.nih.gov/32871349/)
175. [Song et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948429/)
176. [Stewart et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27573920/)
177. [Stray-Pedersen et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17540590/)
178. [Suarez et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25488969/)
179. [Swift et al. (1986)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1684065/)
180. [Texas Department of State Health Services 2025 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2025-annual-wac-report_0226.xlsx)
181. [Texas Department of State Health Services 2026 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx)
182. [Texas Department of State Health Services Prescription Drug Price Disclosure Program data overview](https://www.dshs.texas.gov/prescription-drug-price-disclosure-program/data-overview)
183. [Theis et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37540892/)
184. [Tiet et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32958592/)
185. [Tiet et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11735505/)
186. [Tighilet et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26607469/)
187. [Trouillas et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9094050/)
188. [UnitedHealthcare (2026)](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Med-Nec-Aqneursa.pdf)
189. [van Gool et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40055076/)
190. [van Os et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/28126470/)
191. [van Os et al. (2017b)](https://onlinelibrary.wiley.com/doi/10.1111/dmcn.13424)
192. [van Os et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7035236/)
193. [Vanderkam et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30613860/)
194. [Veenhuis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9291897/)
195. [Veenhuis et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK26468/)
196. [Verhagen et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19535770/)
197. [Verhagen et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22213089/)
198. [Vibert and Vidal (2001)](https://pubmed.ncbi.nlm.nih.gov/11207808/)
199. [Vilozni et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26033643/)
200. [Webber et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13369753/)
201. [Weitering et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13177395/)
202. [Weyer et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17516493/)
203. [WHO Collaborating Centre for Drug Statistics Methodology (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=N07XX27)
204. [Wölke et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32504779/)
205. [Woods and Taylor (1992)](https://pubmed.ncbi.nlm.nih.gov/1377828/)
206. [Woods et al. (1990)](https://pubmed.ncbi.nlm.nih.gov/2338342/)
207. [Zannolli et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22927201/)
208. [Zielen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8604875/)
209. [Zielen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39152028/)

## Related pages
- [Aqneursa (levacetylleucine): Ataxia-telangiectasia](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia) · [Markdown](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia.md)
- [Aqneursa (levacetylleucine) in Ataxia-telangiectasia: Terms and abbreviations](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/terms-and-abbreviations.md)
- [Aqneursa (levacetylleucine): Ataxia-telangiectasia](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/executive-summary) · [Markdown](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/executive-summary.md)
- [Aqneursa (levacetylleucine) in Ataxia-telangiectasia: Product information and disease description](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/product-information-and-disease-description.md)
- [Aqneursa (levacetylleucine) in Ataxia-telangiectasia: Clinical evidence](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/clinical-evidence.md)
- [Aqneursa (levacetylleucine) in Ataxia-telangiectasia: Economic information and modeling report](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/economics) · [Markdown](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/economics.md)
- [Aqneursa (levacetylleucine) in Ataxia-telangiectasia: new drug review](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/monograph/review) · [Markdown](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/monograph/review.md)
- [Aqneursa (levacetylleucine) in Ataxia-telangiectasia: prevalence by geography](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/prevalence) · [Markdown](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/prevalence.md)
- [Aqneursa (levacetylleucine) in Ataxia-telangiectasia: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/cost-effectiveness-analyses.md)
